XBI ETF Analysis: S&P Biotech | NYSE
Healthcare Equity | NYSE, USA | Market Cap: 10.311m USD | 12M Return: 41.5% | US78464A8707 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 1.42B
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
The SPDR S&P Biotech ETF (XBI) is an exchange-traded fund that seeks to track the performance of the S&P Biotechnology Select Industry Index. The fund employs a sampling strategy, investing at least 80% of its total assets in securities comprising the underlying index, which represents the biotechnology segment of the broader S&P Total Market Index.
Launched in January 2006 and classified within the Health category, XBI provides U.S. market exposure to large-cap biotechnology companies. The biotechnology sector generally includes firms engaged in the research, development, and commercialization of therapies, vaccines, and diagnostic technologies, with business models typically driven by product pipelines, clinical trial outcomes, and regulatory approvals from agencies such as the U.S. Food and Drug Administration (FDA).
- FDA approval pipeline catalysts lift biotech index returns
- IRA Medicare drug price negotiations pressure biotech margins
- Fed rate cuts boost high-duration biotech valuations
As of November 11, 2026, the stock is trading at USD 155.06 with a total of 6,990,338 shares traded. Over the past week, the price has changed by +0.06%, over one month by +2.42%, over three months by -1.88% and over the past year by +41.45%.
Current recommended Stop Loss: 148.20 (which is 4.4% or 1.3 ATR below the current price).
S&P Biotech has no consensus analysts rating.